National Advisory Committee on Immunization (NACI). Statement on Haemophilus influenzae type B conjugate vaccines for use in infants and children.
Currently three Haemophilus influenzae type b (Hib) conjugate vaccines are licensed for use in Canada in infants 2 months of age and older: HibTITER (Lederle Laboratories), PedvaxHIB (Merck Sharp & Dohme Canada) and Act-HIB (Pasteur-Mérieux, distributed in Canada by Connaught Laboratories Ltd.). A fourth vaccine, licensed both as a single product (ProHIBIT) or in combination with diphtheria toxoid-pertussis vaccine-tetanus toxoid (DPT-Hib) (Connaught), is limited to use in children 18 months of age or older. The following recommendations incorporate those previously published by the National Advisory Committee on Immunization(1), provide information on Act-HIB (which was licensed in March 1992) and summarize recently published data on the comparative immogenic effects and interchangeability of Hib conjugate vaccines (2-6).
D000907:Antibodies, Bacterial / Q000032:analysis; D016667:Bacterial Capsules; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D002675:Child, Preschool; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control*; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D008583:Meningitis, Haemophilus / Q000276:immunology / Q000517:prevention & control*; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011135:Polysaccharides, Bacterial